<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059512</url>
  </required_header>
  <id_info>
    <org_study_id>NBK-2901-AMNKM</org_study_id>
    <nct_id>NCT02059512</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease</brief_title>
  <acronym>TAMIS</acronym>
  <official_title>Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study evaluate the effect of the method of administration of autologous
      bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts
      in the surgical treatment of coronary heart disease, to assess the degree of effectiveness
      depending on the method of transplantation (intramyocardial, intracoronary).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional estimation of safety:

        1. Assessment of EuroScore II.

        2. The duration of stay in the intensive care unit.

        3. Restoration of cardiac rhythm at the end of the main stage of operation (defibrillation
           / self-recovery).

        4. The time of extracorporeal circulation.

        5. Time of anoxia.

        6. The amount of blood loss by drainage in the 1st day.

        7. The amount of discharge during the second day.

        8. Troponin I at 1, 2, 3 postoperative days.

        9. Postoperative complications (hydrothorax, hydropericardium, arrhythmias).

      Predicting the results of treatment (the effect of a number of parameters):

        1. Age.

        2. Gender.

        3. The body mass index.

        4. Diabetes.

        5. Smoking.

        6. Family history of cardiovascular events.

        7. Duration of ischemic heart disease.

        8. Serum total cholesterol (+ fractions).

        9. Leukocytosis and CRP level (initial level and rate of decrease in the postoperative
           period).

       10. The level of creatinine.

       11. The presence / absence of extracardiac arteriopathy.

       12. The intramyocardial or intracoronary injection of BM-MNCs.

       13. Assessment of the bone marrow: the number of nucleated cells, CD34 +, CD133 +.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality associated with the progression of basic disease</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of functioning grafts in patients with implantation of autologous bone marrow mononuclear cells.</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Estimation of efficiency:
Assessment of myocardial perfusion and metabolism (before and after treatment).
Evaluation of systolic and diastolic myocardial function.
Speckle tracking echocardiography
Patency of grafts within a specified time of treatment (angiography).
Dependence and duration of positive clinical effect on the amount of injected cell material.
Evaluation of the quality of life (Minnesota questionnaire, Seattle questionnaire, SF-36 questionnaire).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>cell Therapy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non cell therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cell therapy 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary artery bypass grafting with administration of autologous bone marrow stem cells</intervention_name>
    <arm_group_label>cell Therapy 1</arm_group_label>
    <arm_group_label>cell therapy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary artery bypass grafting with administration of 0.9 % NaCl (sodium chloride) 0.2 ml</intervention_name>
    <arm_group_label>non cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women from 18 to 80 years

          -  Patients with angina pectoris III-IV functional class

          -  Patients signed informed consent

        Exclusion Criteria:

          -  Intolerance of heparin and HES.

          -  Hypothyroidism and hyperthyroidism.

          -  Associated pathology with a projected lifespan limitation to 3 years.

          -  infection diseases

          -  Simultaneous participation in another study.

          -  Pregnancy.

          -  Severe mental disorder.

          -  Refusal of a patient to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir V Komok</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Pavlov State Medical University of St. Petersburg.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic heart disease,</keyword>
  <keyword>autologous bone marrow mononuclear cells</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 27, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 30, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

